Phase II Study of Carfilzomib-cyclophosphamide-dexamethasone and High-dose Melphalan (HDT) Followed by Randomization Between Observation or Maintenance With Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma After HDT
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Carfilzomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms CARFI
- 11 Oct 2019 This trial has been completed in Finland, according to European Clinical Trials Database.
- 06 Oct 2019 This trial has been completed in Denmark and Sweden, according to European Clinical Trials Database record.
- 31 Aug 2018 Biomarkers information updated